Blood Test for Brain Injury Could Cut Need for Scans
The study was conducted by Paul McMahon, University of Pittsburgh Medical Center, and a team of international researchers, including TRACK-TBI investigators. The researchers analysed blood levels of GFAP-BDP from 215 patients (aged 16-93 years) treated at multiple trauma centres for suspected TBI. They assessed the ability of the blood-based biomarker to predict intracranial injury as compared to the findings on an admission CT and a delayed MRI scan.
Based on the results, the researchers cite a net benefit for the use of GFAP-BDP above imaging-based screening alone and a net reduction in unnecessary scans by 12-30 percent.
"The study demonstrates that serum measurement of GFAP-BDP as a biomarker possesses the necessary characteristics (accuracy, discrimination, calibration, and clinical utility) for improved prediction of radiographically evident injury across the spectrum of TBI," the authors write in the journal report. "Additionally, GFAP-BDP levels were able to discriminate severity of intracranial injury independent of other classic injury predictors. GFAP-BDP also accurately predicted persistence of intracranial injury on imaging performed in the subacute period, again independent of other markers of injury risk."
John T. Povlishock, PhD, Editor-in-Chief of Journal of Neurotrauma and Professor, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, comments on the findings: "This impressive multicentre study joins with other streams of emerging evidence supporting the use of biomarkers as an important tool in the clinical decision making and prediction process.
"Importantly, this study significantly expands upon other studies that speak to the usefulness of GFAP and, specifically, serum-derived GFAP-BDP in identifying those traumatically brain injured patients whose clinical course is complicated by intracranial injury, demonstrating that GFAP-BDP offers good predictive ability, significant discrimination of injury severity, and net benefit in reducing the need for unnecessary scans, all of which have significant implications for the brain injured patient."
Source: Mary Ann Liebert, Inc., Publishers
Image credit: Wikimedia Commons
Published on : Thu, 21 May 2015
We recognize that the best chance any patient has at getting better is a clinician at their bedside with all the right answers and the confidence to act. SonoSite education and training is the industry standard – no other point-of-care ultrasound manufacturer...
The best patient care is your ultimate goal. To achieve this requires confident diagnosis even with daily increases in patient throughput. Built on the foundation of Mindray’s continuous customer insights into clinical needs and the inheritance from...
The SonoSite SII features a new touchscreen user interface with a clinician-driven menu logic that adaptively adjusts to your imaging needs – “what you need, is what you see”. An embedded dual transducer connector allows you to quickly switch between...
Sectra provides a complete solution for primary diagnostics in pathology. The solution includes archiving and storage solutions together with high-end review workstations. It allows pathologists to make their diagnoses and reports with higher precision...